Dr. Drilon on NTRK Rearrangement in Lung Cancer

Alexander Drilon, MD
Published: Thursday, Mar 02, 2017



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

NTRK rearrangements are recurrent gene fusions that are found in a rare minority of patients with lung cancer, explains Drilon. However, looking across other solid tumors, they can be found in head and neck cancer, sarcomas, and breast cancer.

According to Drilon, the interesting thing about TRK fusions, is that they are very actionable in terms of targeted therapy. There are 2 different targeted agents, entrectinib and LOXO-101, that are in phase II testing for any patients who have solid tumors with NTRK rearrangement. Both drugs have achieved dramatic responses, regardless of histology in earlier phase I studies.
 
SELECTED
LANGUAGE


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

NTRK rearrangements are recurrent gene fusions that are found in a rare minority of patients with lung cancer, explains Drilon. However, looking across other solid tumors, they can be found in head and neck cancer, sarcomas, and breast cancer.

According to Drilon, the interesting thing about TRK fusions, is that they are very actionable in terms of targeted therapy. There are 2 different targeted agents, entrectinib and LOXO-101, that are in phase II testing for any patients who have solid tumors with NTRK rearrangement. Both drugs have achieved dramatic responses, regardless of histology in earlier phase I studies.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x